A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.
Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.
How this was made
The 30-second read
Why it matters
The mixed results could lead to a re‑evaluation of VASCEPA's market positioning and potential label expansion, affecting Amarin's valuation.
Market read
First disclosure of EMT2 trial outcomes provides new data that may influence Amarin's stock and the broader EPA‑based therapeutic space.
What to watch
the trial's safety profile remained favorable and the drug is already commercialized for cardiovascular disease, enabling rapid repurposing
Background
Amarin's VASCEPA is an FDA‑approved prescription omega‑3 for cardiovascular risk reduction; the EMT2 trial explores its use in colorectal cancer liver metastasis.
Ticker impact
Amarin reported that its VASCEPA trial (EMT2) missed the primary PFS endpoint but showed a significant overall survival benefit (62% vs 45% at 5 years) in colorectal cancer liver metastasis patients.
potential modest pressure as investors digest missed primary endpoint, offset by upside from overall survival data
Trial data is new and material; primary endpoint miss is negative, but OS benefit is clinically meaningful and may drive future research and market interest.
Market effects
may boost interest in EPA/omega-3 therapeutics for oncology and influence competitor pipelines
limited to US and European biotech markets
modest, as trial pertains to a niche oncology indication
Counterpoint
investors could view the OS benefit as a catalyst outweighing the missed PFS endpoint, supporting a buy on long-term potential
Key entities
- companyAmarin Corporation plc
US‑listed biotech developer of VASCEPA
- institutionUniversity of Leeds
Sponsor of the EMT2 trial
